Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
, and tinnitus [ ; ]. It is not suitable for people with aspirin or salicylate allergy, renal insufficiency, gout, or those who are taking an anticoagulant such as warfarin, or pregnant or breastfeeding women [ ; ; ]. There is potential for drug interactions, including bismuth subsalicylate reducing absorption of doxycycline which may also be required for malaria prophylaxis [ ]. Pepto-bismol ® is not licensed for children younger than 16 years of age due to a possible association between salicylates (...) approach, with 'chemoprophylaxis the rare exception' [ ]. There is a lack of evidence to support the effectiveness of antibiotic prophylaxis for people travelling to countries with low or intermediate risk of travellers' diarrhoea. One double-blind trial in 127 participants found antibiotic treatment (norfloxacin) to be effective in reducing the number of Swedish travellers developing diarrhoea in high-risk countries (Africa, Asia, or Latin America, p = 0.0004) but not for those travelling to low-risk
Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Anti-malarial drugs can make a significant contribution to the control of malaria in endemic areas when used for prevention as well as for treatment. Chemoprophylaxis is effective in preventing deaths and morbidity from malaria, but it is difficult to sustain for prolonged periods, may interfere with the development of naturally acquired immunity and will facilitate the emergence and spread of drug (...) resistant strains if applied to a whole community. However, chemoprophylaxis targeted to groups at high risk, such as pregnant women, or to periods of the year when the risk from malaria is greatest, can be an effective and cost effective malaria control tool and has fewer drawbacks. Intermittent preventive treatment, which involves administration of anti-malarials at fixed time points, usually when a subject is already in contact with the health services, for example attendance at an antenatal
Daley (National Jewish Health, USA), Jimmy Dorabjee (Asian Harm Reduction Network, Australia), Maria Golovanevskaya (independent consultant, USA), Teodora Groshkova (European Monitoring Centre for Drugs and Drug Addiction, Portugal), Mauro Guarinieri (the Global Fund to Fight AIDS, T uberculosis and Malaria, Switzerland), Karyn Kaplan (Treatment Action Group, USA), Adeeba Kamarulzaman (University of Malaya, Malaysia), Adnan Khan (Research and Development Solutions, Pakistan), Bijay Pandey (Asian (...) was subsequently endorsed at the highest political levels by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), the United States (US) President’s Emergency Plan for AIDS Relief (PEPFAR), the UNAIDS Programme Coordinating Board, the United Nations (UN) Commission on Narcotic Drugs, the UN General Assembly, and the UN Economic and Social Council. However, for PWID, access to this recommended package of services remains inadequate (4). The nine evidence-based interventions that make up
, Mycobacterium marinum In?uenza vaccine Travel safety Follow food and water safety practices above; Consult CDC travel page for current preventive measures by geographic area (wwwnc.cdc.gov/ travel), with special attention to recommendations for those travelers who are immunocompromised; Chemoprophylaxis and mosquito protection by area Examples by geographic area: N meningitidis (the Hajj, sub-Saharan Africa), Japanese encephalitis virus, Yellow fever virus; Salmonella typhi, malaria, chikungunya, dengue HAV
(The University of Hong Kong, China) and Tariq Zafar (Nai Zindagi, Pakistan). Representatives of UN agencies and other partners Jenny Butler (United Nations Population Fund, USA), Monica Ciupagea (United Nations Office on Drugs and Crime, Austria), Clifton Cortez (United Nations Development Programme Asia–Pacific Regional Centre, Thailand), Karl Dehne (Joint United Nations Programme on HIV/AIDS, Switzerland), Mauro Guarinieri (The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), Fabienne (...) and Gottfried Hirnschall (Department of HIV). Funding The Unified Budget, Results and Accountability Framework of the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) provided the funding to support this work, including the systematic reviews of evidence, evidence compilation, convening of the expert meeting, and development, editing, and printing of the guidelines. The Global Fund to Fight AIDS, Tuberculosis and Malaria provided funding
agencies and other partners Martin Auton (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), Smiljka De Lussigny (UNITAID, Switzerland), Peter Ghys (UNAIDS, Switzerland), Peter Godfrey Fausett (UNAIDS, Switzerland), Michael Hahn (UNAIDS, Switzerland), Chewe Luo (UNICEF , USA), Atienno Ojoo (UNICEF , Denmark), Carlos Passerelli (UNAIDS, Switzerland), Annette Reinisch (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland) and Landry Tsague (UNICEF). Funding Grants from
Project, China). Representatives of United Nations agencies and other partners Martin Auton (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), Smiljka De Lussigny (UNITAID, Switzerland), Peter Godfrey Fausett (UNAIDS, Switzerland), Chewe Luo (UNICEF, Kenya), Atienno Ojoo (UNICEF) and Carlos Passerelli (UNAIDS, Switzerland). Funding Grants from the Bill and Melinda Gates Foundation, United States Agency for International Development, United States Centers for Disease Control
), Neeraj Dhingra (Ministry of Health and Family Welfare, India), Miriam Franchini (Ministry of Health, Brazil), Mehdi Karkouri (Centre Hospitalier Universitaire, Ibn, Morocco), Segundo Leon (Universidad Nacional Mayor de San Marcos, Peru), Joseph Tak Fai Lau (Chinese University of Hong Kong, Hong Kong SAR, China), Gertrude Ncube (Ministry of Health, Zimbabwe), Lisa Nelson (Global Fund to Fight Tuberculosis, HIV/AIDS and Malaria, Switzerland), Anne Ng’ang’a (National AIDS Control Programme, Kenya (...) , Singapore), Nitika Pant Pai (McGill University, Canada), Bharat Parekh (CDC, USA), John Parry (Public Health England, United Kingdom), Praphan Phanuphak (Thai Red Cross, Thailand), Andrew Phillips (University College of London, United Kingdom), Dorthe Raben (Copenhagen HIV Programme, HIV Europe, Denmark), Miriam Sabin (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), Joshua Saloman (Harvard University, USA), Monisha Sharma (University of Washington, USA), Daniel Shodell (CDC
to prevent HIV with more simplified approaches to post- exposure prophylaxis and simplifying the indications on the use of co-trimoxazole to prevent opportunistic infections, bacterial infections and malaria. Consistent with previous WHO guidelines, these guidelines are based on a public health approach that considers feasibility and effectiveness across a variety of settings. The key principles of availability, affordability, acceptability, accessibility and quality have been considered in producing (...) -antiretroviral therapy (pre-ART) care in low- and middle-income countries. The focus then was on people with advanced and severe disease with limited access to ART. Recently, new evidence has emerged that, with effective scaling up of ART, co-trimoxazole prophylaxis has a broader benefit beyond preventing Pneumocystis jirovecii pneumonia and reducing HIV-associated mortality among people with low CD4 counts. Specifically, the value of using co-trimoxazole prophylaxis to prevent malaria and severe bacterial
Tafenoquine: the new kid on the block. This is a review of tafenoquine, a new antimalarial drug. Here we examine the recent literature supporting the use of tafenoquine and summarize the opportunities and challenges for its well tolerated use worldwide.Tafenoquine was recently approved by the US Food and Drug Administration for the treatment of dormant liver stage (hypnozoite) in Plasmodium vivax and for malaria prophylaxis. Single-dose tafenoquine provides equivalent efficacy to 14 days (...) of primaquine for radical cure in P. vivax, and it can be dosed weekly to prevent malaria. However, tafenoquine can only be used in patients with normal G6PD activity and is contraindicated in children and during pregnancy or in lactating mothers with infants of deficient or unknown G6PD status.Tafenoquine's long half-life allows a single dose to achieve radical cure, and weekly dosing for chemoprophylaxis to provide an exciting therapeutic option for patient care and as a new weapon for malaria control
The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? The presence of ongoing local malaria transmission, identified though local surveillance and reported to regional WHO offices, by S-E Asian countries, forms the basis of national and international chemoprophylaxis recommendations in western countries. The study was designed to examine whether the strategy of using malaria transmission in a local population was an accurate estimate (...) and tourism statistics collected on entry of tourists to the destination countries.In the destination countries, mean malaria rates in endemic countries ranged between 0.01 in Korea to 4:1000 population per year in Lao PDR, with higher regional rates in a number of countries. Malaria cases imported into the 13 countries declined by 47% from 140 cases in 2003 to 66 in 2008. A total of 608 cases (27.3% Plasmodium falciparum (Pf)) were reported over the six years, the largest number acquired in Indonesia
The challenge of diagnosing Plasmodium ovale malaria in travellers: report of six clustered cases in French soldiers returning from West Africa. Plasmodium ovale is responsible for 5% of imported malaria in French travellers. The clinical and biological features of six clustered cases of P. ovale malaria in an army unit of 62 French soldiers returning from the Ivory Coast are reported.All patients were symptomatic and developed symptoms on average 50 days after their return and 20 days after (...) the end of chemoprophylaxis (doxycycline). Clinical features included fever (6/6), mostly tertian (4/6), aches (6/6), nausea (3/6), abdominal pain (2/6), diarrhoea (2/6), or cough (2/6). Thrombocytopaenia was lower than 100,000/mm3 in half the cases only, and the haemoglobin count was normal for all patients. The diagnosis was made after at least three thick and thin blood smear searches. Parasitaemia was always lower than 0.5%. All rapid diagnostic tests were negative for HRP2 and pLDH
-181) after travel; 98% were outpatients. Of 581 confirmed diagnoses, the most common diagnosis category was gastrointestinal (45%). Acute diarrhoea was the most common gastrointestinal diagnosis (113 of 261; 43%). Thirty-one (7%) students had vector-borne diseases [14 (41%) malaria and 11 (32%) dengue]. Three had vaccine-preventable diseases (two typhoid; one hepatitis A); two had acute human immunodeficiency virus infection.Students experienced travel-related infections, despite the majority (...) having a pre-travel consultation. US students should receive pre-travel advice, vaccinations and chemoprophylaxis to prevent gastrointestinal, vector-borne, sexually transmitted and vaccine-preventable infections.
hypersensitivity, or allergic disease diagnosed and treated by a physician. Antimalarial medicine intake or returning from a malaria-endemic area within the 12 last months before the first IMP administration. Planning to visit a country requiring antimalarial chemoprophylaxis during the study period. History of adverse reaction after a previous mefloquine intake. Contraindication for the use of Aricept® or for one of its excipients. Contraindication for the use of piperidine derivative compounds or for other
A survey on outcomes of accidental atovaquone-proguanil exposure in pregnancy. Malariachemoprophylaxis options in pregnancy are limited, and atovaquone-proguanil (AP) is not recommended because of insufficient safety evidence. An anonymous, internet-based survey was disseminated to describe outcomes of pregnancies accidentally exposed to AP. Outcomes of interest included miscarriage (defined as pregnancy loss before 20 weeks), stillbirth (defined as pregnancy loss at or after 20 weeks (...) ), preterm birth or live birth prior to 37 weeks, and the presence of congenital anomalies.A total of 487 women responded and reported on 822 pregnancies. Of the 807 pregnancies with information available on exposure and outcomes, 10 (1.2%) had atovaquone-proguanil exposure, all in the first trimester, and all resulted in term births with no birth defects.Use of an anti-malarial not recommended in pregnancy is likely to occur before the woman knows of her pregnancy. This study adds to the limited
diarrhea (8%), viral syndrome (6%), acute bacterial diarrhea (5%) and chronic diarrhea (4%). Species was reported for 973 (90%) of 1079 patients with malaria, predominantly Plasmodium falciparum acquired in sub-Saharan Africa. Of 584 (54%) with malariachemoprophylaxis information, 92% took none or incomplete courses. Thirteen deaths were reported, over half of which were due to malaria; others succumbed to pneumonia, typhoid fever, rabies, melioidosis and pyogenic abscess.Diarrheal illness was a major (...) cause of morbidity. Malaria contributed substantial morbidity and mortality, particularly among business travelers to sub-Saharan Africa. Underuse or non-use of chemoprophylaxis contributed to malaria cases. Deaths in business travelers could be reduced by improving adherence to malariachemoprophylaxis and targeted vaccination for vaccine-preventable diseases. Pre-travel advice is indicated for business travelers and is currently under-utilized and needs improvement.
medications used for malariachemoprophylaxis, with or without other anti-malarial treatment, for more than 4 weeks (duration of anti-malarial course) and part of the treatment received within the 2 weeks before vaccination, contraindicating intradermal vaccination The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. Contacts and Locations Go to Information from the National Library of Medicine To learn more about
and management practices for SCD care at these centres were also evaluated using pretested self-administered questionnaires and observational checklists.The majority of CHWs (167/182 [91.8%]) knew that SCD is an inheritable blood disorder. However, only 32.4% and 26.4% knew that SCD can be diagnosed in the prenatal and neonatal periods, respectively. Also 37.4%, 49.5% and 67.6% knew about the role of chemoprophylaxis (folic acid/penicillin), adequate fluids and malaria prevention, respectively, in SCD care